Ivim runs the most responsive dosing on this page. Rather than moving everyone up a fixed ladder, it reviews and adjusts weekly according to how you are doing. For a medication whose tolerability varies enormously between people, that is a real engineering advantage and it is the reason to consider Ivim at all.
It is also the only part of the model built around you. Everything surrounding that titration engine is generic weight care focused on the medication rather than the person taking it.
Here is how Ivim Health reads against each promise of the Whole-Woman Charter. Each promise is marked none, partial or strong; price is shown but is never part of the rating. GLP-1 medications are not a treatment for endometriosis.
Live telehealth with weekly dose review at $208 a month, drawing on both 503A and 503B pharmacies. Dose fit is the only strong row on this scorecard and it earns it — this is better titration than several providers charging more. Human help sits at partial, and the first three Charter rows score zero because no whole-person or gynecologic framing is published.
Weekly adjustment responds to what you report about the medication — appetite, nausea, weight. It has no visibility into a flare, and no framework for distinguishing a side effect from a symptom of something you already live with. That distinction can be genuinely difficult, and here you would be making it alone. As with any dual-sourcing provider, confirm which pharmacy type will fill your prescription.
Put these to Ivim Health in writing, and keep the reply.
Ivim earns a low Charter rating and still suits a specific reader: someone whose difficulty has been tolerating the medication rather than being heard about everything else. The titration is a genuine strength and it is the honest reason to choose this one.
What is above comes from what this provider chooses to publish, and providers revise their terms without saying so — treat it as a starting point and check it yourself. Havelle is editorial, not clinical: none of this is medical advice, and GLP-1 medications are not a treatment for endometriosis.